Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03497806 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
A Phase 2 study of Clostridium Difficile Infection and CDI, sponsored by Finch Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT03497806 is a Phase 2 study of Clostridium Difficile Infection and CDI that has completed, run by Finch Research and Development. The registered enrollment target is 132 participants, below the 12,056-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03497806, a Phase 2 study of Clostridium Difficile Infection and CDI, has completed, sponsored by Finch Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible for direct study entry into CP101-CDI-E02. Subjects who are experiencing recurrent CDI will undergo screening procedures. Subjects who meet eligibility criteria will be eligible to be enrolled in he study and administered CP101. Approximately 200 subjects will receive CP101. The treatment duration will be 1 day. Subjects will be monitored for recurrence of CDI, safety, and tolerability for 24 weeks following receipt of CP101. The primary efficacy and safety endpoints will be evaluated at 8 weeks post treatment, and all subjects will continue to be followed for an additional 16 weeks for safety and recurrence of CDI.
Conditions Studied
Interventions
- BIOLOGICAL CP101
Study Locations (20)
California
- Los Angeles - Los Angeles
- Murrieta - Murrieta
- Oakland - Oakland
- San Diego - San Diego
- San Francisco - San Francisco
Florida
- Jacksonville - Jacksonville
- Naples - Naples
- Pinellas Park - Pinellas Park
- Tampa - Tampa
Illinois
- Burr Ridge - Burr Ridge
- Chicago - Chicago
- Evanston - Evanston
- Maywood - Maywood
Connecticut
- Bridgeport - Bridgeport
- Hamden - Hamden
Arizona
- Scottsdale - Scottsdale
Colorado
- Aurora - Aurora
District of Columbia
- Washington DC - Washington D.C.
Georgia
- Atlanta - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2021-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03497806
The ClinicalTrials.gov registry entry for NCT03497806 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,056-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The listed sponsor is Finch Research and Development, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention - of which CP101 is the first listed.
NCT03497806 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03497806 about?
NCT03497806 is a clinical study titled "Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection". This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible for direct study entry into CP101-CDI-E02. Subjects who are experiencing...
What is the current status of trial NCT03497806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2018-05-01. Estimated completion is 2021-04-01.
What conditions does trial NCT03497806 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection, CDI, Recurrent Clostridium Difficile Infection, C. Difficile, C. Diff.
What interventions are being tested in trial NCT03497806?
The interventions under investigation include: CP101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03497806?
This trial is sponsored by Finch Research and Development, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03497806 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
RECRUITING · Phase 2
-
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation
COMPLETED · Phase 2
-
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
COMPLETED · Phase 2
-
Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
COMPLETED · Phase 2
-
Study of CB-183,315 in Participants With Clostridium Difficile Infection
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.